EVOLUTION AT MERCK - INVENTING FOR LIFE

CHINA BECOMING NEW PILLAR OF GROWTH 43% Merck 30% MNC 25% 24% 23% Pivoting portfolio to innovation KEYTRUDA Lynparza (pembrolizumab) Injection 100 mg olaparib tablet me GARDASIL.9 Human Papillomavirus 9-valent Vaccine, Recombinant Reaching more patients & expanding customer base LENVIMA (lenvatinib) capsules GARDASIL Humaan Papillomavirusvacci typen 6,11,16,18 inant, gradsorbeerd bridion (sugammadex)tion 100 mg/mL "equivalent to 108.8 ng/ml sugammade sodium Januvia (sitagliptin) 25mg, 50mg, 100mg tablets 18% 18% 18% 16% 15% 14% 12% --9%- 7% 4% MNC MNC MNC MNC MNC MNC MNC MNC MNC MNC MNC MNC MNC 1Only includes Human Health portion of business Average: 11% Fastest growing multinational pharmaceutical company Growth percentage over prior 18 months through 1Q 2019 for Top 15 multinationals.. Source: R&D-Based Pharmaceutical Association Committee (RDPAC) Report MERCK Frank Clyburn INVENTING FOR LIFE 28

View entire presentation